Translate page

Logo ASH 3

January 2016 - Important CML news was presented at the 58th Meeting of the American Society of Hematology (ASH) in San Diego. This included; data to help guide treatment discontinuation and TFR monitoring, Phase I results of a new tyrosine kinase inhibitor and new findings on the use of generics. We have compiled a selection of these CML highlights to assist you follow the latest scientific advancements in CML.

CML experts giving their personal perspectives

We are delighted to introduce three CML experts providing their personal perspectives on latest scientific findings and highlights from ASH. You can listen to:

  • Associate Professor Susan Branford speaking about; treatment-free remission studies, new data on optimal timing for monitoring after stopping therapy, additional chromosomal abnormalities and next-generation sequencing.
  • Professor Jorge Cortes speaking about; different aspects of treatment discontinuation, Phase I data for a new tyrosine kinase inhibitor, predictive markers and data supporting the use of imatinib generics.
  • Dr Fabio Efficace speaking about; the importance of QoL assessment in CML, the correlation between QoL and adherence to therapy, QoL data presented and the meeting and available measuring instruments.   

Top CML stories from ASH 2016

As a special edition of our monthly CML news service we are pleased to provide you with five stories featuring CML highlights presented at the ASH meeting.                    

  • EURO-SKI findings may help guide TKI discontinuation
    EURO-SKI trial results presented at the 2016 Annual Meeting & Exposition of the American Society of Hematology add to knowledge on the best practice for discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia patients.
  • TFR monitoring frequency, QoL impact reported at ASH 2016
    Posters from the 2016 American Society of Hematology Annual Meeting & Exposition suggest that patient monitoring after discontinuation of tyrosine kinase inhibitor therapy may be feasible on a 2-monthly basis, but that patient-reported quality of life may not improve after treatment is stopped.

The CML news service is provided in partnership with MedwireNews, Springer Healthcare’s independent news bureau.


ASH congress materials on CML

All abstracts presented at the meeting are now available on the website of the American Society of Hematology. Here you will find:

More summaries, expert opinions and downloadable slides are available on the website of Clinical Care Options oncology.